pubmed.ncbi.nlm.nih.gov

Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer - PubMed

  • ️Fri Jan 01 2010

Review

Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer

Chitta Ranjan Patra et al. Adv Drug Deliv Rev. 2010.

Abstract

The targeted delivery of a drug should result in enhanced therapeutic efficacy with low to minimal side effects. This is a widely accepted concept, but limited in application due to lack of available technologies and process of validation. Biomedical nanotechnology can play an important role in this respect. Biomedical nanotechnology is a burgeoning field with myriads of opportunities and possibilities for advancing medical science and disease treatment. Cancer nanotechnology (1-100 nm size range) is expected to change the very foundations of cancer treatment, diagnosis and detection. Nanomaterials, especially gold nanoparticles (AuNPs) have unique physico-chemical properties, such as ultra small size, large surface area to mass ratio, and high surface reactivity, presence of surface plasmon resonance (SPR) bands, biocompatibility and ease of surface functionalization. In this review, we will discuss how the unique physico-chemical properties of gold nanoparticles may be utilized for targeted drug delivery in pancreatic cancer leading to increased efficacy of traditional chemotherapeutics.

Copyright 2009 Elsevier B.V. All rights reserved.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Chemical formula of some anti-cancer drugs and EMD72000), Trastuzumab (Herceptin)] that inhibit ligand binding to EGFRs and small-molecule tyrosine kinase inhibitors (TKIs).

Figure 2
Figure 2

Release of125I-C225 and [3H-Gem] from the nanoconjugate in cell growth media mouse plasma. Figure 2A demonstrating the release of C225 from Au- [125I-C225]-Gem in RPMI and in mouse plasma over time. Distribution of 125I-C225 in supernatant and pellet was quantified by radioactivity measurement in a gamma counter. Figure 2B demonstrating the release of 3H-Gem from Au-C225-[3H-Gem] in RPMI and in mouse plasma over time. Distribution of 3H-Gem in the supernatant and in the pellet was quantified by radioactivity measurement in a scintillation counter. Reprinted with permission from Ref. [173], Chitta Ranjan Patra, Sheng Cao, Stephanie Safgren, Resham Bhattacharya, Matthew M. Ames, Vijay Shah, Joel M. Reid, and Priyabrata Mukherjee, Intracellular fate of a targeted delivery system. J. Biomed. Nanotechnol. 4, 508–514 (2008). Copyright©American Scientific Publishers,

www.aspbs.com

.

Figure 3
Figure 3

In vivo targeting of the nanoconjugate and its therapeutic efficacy. A, the quantification of the amount of gold taken up by the tumor, kidney, and liver under different treatment groups (n = 3). A comparative bioluminescence image from the mice treated with a mixture of C225 and gemcitabine (C225 + Gem; B) or Au-C225-Gem (C) i.p. (n = 10). D, effect of different treatment groups on tumor growth inhibition in vivo (left). Tumor volume was measured after sacrificing the mice at the end of the experiment. Right, plasma concentration of gold over time determined by ICP analysis. Blood samples were collected from the mice under isoflurane anesthesia at different time points in heparinized tubes containing tetrahydrouridine to prevent gemcitabine degradation by cytidine deaminase after i.v. drug administration. Reprinted with permission from Ref. [6]. Patra et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 68 (2008) 1970–1978. Copyright © 2008 American Association for Cancer Research;

http://www.aacr.org

.

Similar articles

Cited by

References

    1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004, Ca-a Cancer Journal for Clinicians. 2004;54:8–29. - PubMed
    1. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum ca 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann. Surg. Oncol. 2004;11:644–649. - PubMed
    1. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic adenocarcinoma: The actual 5-year survivors. Journal of Gastrointest. Surg. 2008;12:701–706. - PubMed
    1. Mahalingam D, Giles F. Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opin. Ther. Targets. 2008;12:1389–1401. - PubMed
    1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK. Bethesda, md: national cancer institute; 2009. SEER cancer statistics review, 1975–2006. http://seer.Cancer.Gov/csr/1975_2006.

Publication types

MeSH terms

Substances